Sharma A, Mayhew E, Straubinger R M
Department of Pharmaceutics, University at Buffalo, State University of New York, Amherst 14260-1200.
Cancer Res. 1993 Dec 15;53(24):5877-81.
Taxol is a promising agent for use in ovarian cancer and other malignancies. One problem associated with taxol is its low aqueous solubility, requiring Cremophor EL (polyethoxylated castor oil) and ethanol as excipients (Diluent 12); these agents cause serious adverse effects. Liposomes containing taxol and phospholipid (in a 1:33 mole ratio, respectively) were prepared from phosphatidylglycerol and phosphatidylcholine in a 1:9 mole ratio. Antitumor effect was evaluated against Colon-26, a taxol-resistant murine tumor. Given as 1, 4, or 9 injections, free taxol given i.v. in Diluent 12 was ineffective at delaying tumor growth at doses < or = 30 mg/kg per injection (the maximum tolerated dose). In contrast, taxol-liposomes were well tolerated at doses greater than or equal to the maximum tolerated dose of free taxol and showed significant tumor growth inhibition at 10-45 mg/kg per injection.
紫杉醇是一种有望用于治疗卵巢癌和其他恶性肿瘤的药物。与紫杉醇相关的一个问题是其水溶性低,需要聚氧乙烯蓖麻油(Cremophor EL)和乙醇作为辅料(稀释剂12);这些辅料会引起严重的不良反应。分别以1:9摩尔比的磷脂酰甘油和磷脂酰胆碱制备了含紫杉醇和磷脂(摩尔比为1:33)的脂质体。以对紫杉醇耐药的小鼠肿瘤Colon-26为模型评估了其抗肿瘤效果。静脉注射稀释剂12中的游离紫杉醇,当注射剂量≤30mg/kg(最大耐受剂量)时,给予1次、4次或9次注射均无法有效延缓肿瘤生长。相比之下,紫杉醇脂质体在剂量大于或等于游离紫杉醇最大耐受剂量时耐受性良好,并且在每次注射10 - 45mg/kg时显示出显著的肿瘤生长抑制作用。